Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Endometrial Cancer Recurrent × TIC10 compound × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 2 Glioblastoma 2 Endometrial Neoplasms 2 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Meningioma 1 Glioma 1 Endometrial Cancer Recurrent 1 Diffuse Intrinsic Pontine Glioma 1 Breast Neoplasms, Male 1

Interventions

TIC10 compound 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03485729 2024-12-24

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Jazz Pharmaceuticals

Phase 2 Terminated

27 enrolled 11 charts

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡